AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Finance Biggo

Published November 11, 2026

Stifel's Head of Therapeutics Research Paul Matteis shares his take on biotech and ...

Read the full story at Finance Biggo

Stifel's Paul Matteis weighs Biogen's litifilimab lupus risk/reward, Alnylam's reset ATTR expectations and 340B pressure, and psychedelic launch.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech